Last reviewed · How we verify

NCT05270967: fdg

FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination

Completed Last updated 8 March 2022
What this trial tests

trial testing F-18 FDG PET/CT imaging in Vaccine Reaction in 129 participants. Completed in 10 January 2022.

Timeline
29 July 2021
Primary endpoint
10 January 2022
10 January 2022

Quick facts

Lead sponsorKocaeli University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment129
Start date29 July 2021
Primary completion10 January 2022
Estimated completion10 January 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kocaeli University

Who can join

18 and older, any sex, with Vaccine Reaction or Oncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vaccine Reaction

Currently open trials in the same condition.

Other Kocaeli University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing